Christos Argyropoulos, PhD
Nephrology · Albuquerque, NMNPI 1194968529
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,761 of the $32,334 with a category attached, or 89.0%. 10 manufacturers reported payments, led by Bayer at 34.0% of the total. Reporting peaked in 2021 at $9,271 and has fallen 99.4% since, to $57 in 2025. Among nephrology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $923.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$11K
- Baxter Healthcare$7K
- Grifols, S.A.$5K
- Quanta Dialysis Technologies Inc$5K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Grifols Shared Services North America, Inc.$800
- plus $204 from 4 others
Across 93 payments — averaging $573.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$41K
- Boehringer Ingelheim International GmbH$11K
- Novo Nordisk AS$1K
- Gilead$1K
What the payments were for
- Consulting fees$28,76189%
- Speaking & faculty fees$2,0006%
- Travel & lodging$8343%
- Food & beverage$6052%
- Education$1330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $11,006 |
| Baxter Healthcare | 11 | $7,154 |
| Grifols, S.A. | 1 | $5,250 |
| Quanta Dialysis Technologies Inc | 5 | $5,200 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $2,720 |
| Grifols Shared Services North America, Inc. | 1 | $800 |
| Amgen | 1 | $72 |
| Idorsia Pharmaceuticals US Inc | 1 | $60 |
| AstraZeneca | 1 | $45 |
| Travere Therapeutics, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - HD$6,909
- Non-Covered$5,973
- Kerendia$4,977
- SC+ Hemodialysis Machine$3,200
How this compares
$32,334 in reported general payments places this provider in the 95th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 46 | $37,369 |
| JardianceEmpagliflozin | 33 | $23,165 |
| TrulicityDulaglutide | 13 | $18,687 |
| FarxigaDapagliflozin Propanediol | 21 | $13,978 |
| Cinacalcet Hcl | 15 | $7,212 |
| Calcium Acetate | 30 | $3,340 |
| Sevelamer Carbonate | 22 | $2,700 |
| Nifedipine ErNifedipine | 35 | $1,380 |
| Eplerenone | 20 | $1,070 |
| Tamsulosin Hcl | 22 | $587 |
| Lisinopril | 36 | $441 |
| Famotidine | 29 | $417 |
| Calcitriol | 22 | $384 |
| Atorvastatin Calcium | 45 | $354 |
| Amlodipine Besylate | 53 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $11,006 | $37,36946 claims |
| AstraZenecaFarxiga | $45 | $13,97821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Dale EricksonAlbuquerque$6K
- Lei ChenAlbuquerque$5K
- Sonam KundelingAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.